Celcuity (NASDAQ:CELC) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Celcuity (NASDAQ:CELC) released its quarterly earnings data on Monday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.13), Zacks reports.

Celcuity Trading Down 1.3 %

NASDAQ:CELC opened at $10.11 on Tuesday. The stock has a market cap of $375.38 million, a price-to-earnings ratio of -3.87 and a beta of 0.65. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. Celcuity has a 1 year low of $8.53 and a 1 year high of $22.04. The business has a fifty day moving average of $11.18 and a 200-day moving average of $12.91.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on CELC. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research note on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price objective on shares of Celcuity in a research report on Tuesday. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $30.17.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.